Poly Medicure Limited (POLYMED) Fair Value & Analysis

Healthcare · IN · Market cap ₹174B

Below-average quality, and screening another 68% overvalued on our models.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case (₹694.54). The favourable scenario is already priced in.
• Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 23, 2026.

How to read this chart

60‑month range ₹663.65 – ₹2,997 · fair‑value band ₹416.72 – ₹694.54 · the ₹1,718 price screens above the ₹555.63 fair value. Dashed = 300-day average. As of Aug 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Poly Medicure Limited (POLYMED) currently trades at ₹1,718, while our model-based Fair Value estimate is ₹555.63, implying the stock looks roughly 67.7% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Poly Medicure Limited generated revenue of ₹20.0B at a net margin of 15.8%. Revenue grew 30.3% year over year. It earns a return on equity of 10.9%. Net debt stands at ₹2.9B. Fundamentals as of Aug 23, 2026

Our scenario range runs from ₹416.72 (bear case) to ₹694.54 (bull case); at ₹1,718, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 45% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at -68%, POLYMED screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (₹897.86) versus Asset-Based (₹205.32). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Poly Medicure Limited manufactures and sells medical devices in India and internationally. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I.V.

Full company description

Poly Medicure Limited manufactures and sells medical devices in India and internationally. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I.V. infusion sets, manifolds, safety winged infusion sets, T-type extension sets, stylet/mandrin with luer locks, vial access spikes, measured volume fluid administration sets, extension lines, central venous catheters, CVP manometers, needle free connectors, pre filled syringes, vascular accesses, and blood administration sets. The company also provides nasogastric and infant feeding tubes, gastro-duodenal feeding tubes, and umbilical catheters; urine collection bags, foley balloon catheters, irrigation sets, urine drainage catheters, and urine collection bags with measured volume meters; and endotracheal and tracheostomy tubes, mucus extractors, ventilator circuits, bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. It offers oncology products; endo bronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oro-pharyngeal airways, variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, and aerosol therapy masks; and dialyzers, blood lines, dialysis systems, fistula needles, haemodialysis catheters, and peritoneal dialysis and transfusion sets. The company provides closed wound suction units, under water seal drainage systems, high pressure vacuum bottles, yankauer suction sets, and thoracic drainage catheters; blood collection tubes, safety blood collection sets, blood collection needles, ESR pipettes, and luer adaptors; blood bag systems; face protective shields, polymasks, and viral transport medium kits; and insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, universal caps, and ECG electrodes. The company was incorporated in 1995 and is based in New Delhi, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Poly Medicure Limited reported revenue of ₹18.8B in FY2026 versus ₹9.2B in FY2022, a compound +19.6%/yr. Reported net income was ₹3.3B in FY2026, compounding +22.6%/yr from FY2022.

POLYMED screens 68% overvalued. Compare with Intuitive Surgical, Inc →

Peer Group

Medical Instruments & Supplies · 205 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 23, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.